Ann: Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study, page-102

I did listen to this webinar. There were three presenters,
Endpoints has just put up the questions asked, and answers, this was not on the webinar, and is interesting reading.
I will put a link here. The last point , i.e. , the relative ease , for running trials in OV therapy, with an IV dose needing .
minutes, compared to IV infusion in a clinic for four hours, is worth noting.
A brief summary:
Paul Peter Tak, Candel therapeutics, works with HSV virus, trial in Prostate cancer, IT , no IV. Study started 2011, completing Dec 2024 . ( talk about needing patience) also study into glioblastoma.

Howard Kaufman , CEO Ankara, also intratumoral only. Only “ clinical” work has been in dogs! Humans” coming soon”

Adina Pelusio . With KaliVir.. also using vaccinia, working on IV use. Again only clinical work in dogs. An unlisted company. She was impressive.

issuses discussed were , needing good study design, targeting the right tumour, RECIST esp tumour size, with regard to tumour pseudo progression.

All this prompted me to have a good look at T-VEC. AMGEN is a huge company, T-VEC is a good earner, but by no means their most important. Notably, they have no ongoing research into OV’s. I guess they just buy out what they want.

All up, I think if there is another update webinar in this field, I believe that YF will be invited . OV’s are a tough field, these speakers have been in it for decades. I’m feeling very good about CF 33 , etc

https://endpts.com/oncolytic-virus-experts-discuss-biggest-lessons-from-past-failures/